United Therapeutics Corporation (UTHR) Presents at Bernstein 2nd Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/23/25
United Therapeutics Corporation to Review Data from the Successful TETON-2 Pivotal Study of Nebulized Tyvaso® in Idiopathic Pulmonary FibrosisBusiness Wire • 09/19/25
United Therapeutics Corporation to Present at the Bernstein 2nd Annual Healthcare ForumBusiness Wire • 09/16/25
United Therapeutics to Feature Clinical Data Across its Commercial and Development Portfolio at the European Respiratory Society CongressBusiness Wire • 09/12/25
United Therapeutics Corporation (UTHR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)Seeking Alpha • 09/08/25
United Therapeutics: Nebulized Tyvaso Label Expansion Possible For IPF After Study WinSeeking Alpha • 09/04/25
Why United Therapeutics Just Catapulted 35%, Pulling Insmed, Liquidia With ItInvestors Business Daily • 09/02/25
United Therapeutics Corporation Announces TETON-2 Pivotal Study of Tyvaso® Meets Primary Endpoint for the Treatment of Idiopathic Pulmonary FibrosisBusiness Wire • 09/02/25
Why Is United Therapeutics (UTHR) Up 11.9% Since Last Earnings Report?Zacks Investment Research • 08/29/25
United Therapeutics Corporation to Present at the Morgan Stanley 23rd Annual Global Healthcare ConferenceBusiness Wire • 08/29/25
United Therapeutics: Critical September IPF Data Catalyst Sets Up Momentous YearSeeking Alpha • 08/27/25
United Therapeutics Corporation Announces $1 Billion Accelerated Share Repurchase ProgramBusiness Wire • 08/01/25
UTHR Q2 Earnings Miss Estimates, Higher Tyvaso Sales Aid Revenues Y/YZacks Investment Research • 07/31/25
Compared to Estimates, United Therapeutics (UTHR) Q2 Earnings: A Look at Key MetricsZacks Investment Research • 07/30/25
United Therapeutics Corporation Reports Record Second Quarter 2025 Financial ResultsBusiness Wire • 07/30/25
United Therapeutics (UTHR) Crossed Above the 50-Day Moving Average: What That Means for InvestorsZacks Investment Research • 07/24/25